GlassScriptPhysician profile
John D Picano
NPI 1003202615
$2,719.94
in general payments reported to CMS, 2019-2025
25 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $445 · 2023: $369 · 2024: $644 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.64 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.60 | 2021-2025 | |
| Janssen Biotech, INC. | $507.16 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $217.00 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.87 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $178.66 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $130.43 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $105.98 | 2023-2025 | |
| Celgene Corporation | $65.99 | 2022 | |
| Qol Medical, LLC | $61.98 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $52.77 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $43.99 | 2024 | Dificid |
| Madrigal Pharmaceuticals | $43.38 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $42.76 | 2023-2024 | Rebyota |
| Exact Sciences Corporation | $40.79 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Braintree Laboratories, INC. | $39.38 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.12 | 2023-2024 | Cyltezo |
| Organon LLC | $37.42 | 2024-2025 | Hadlima |
| Pfizer INC. | $21.75 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.25 | 2025 | |
| Sandoz INC. | $19.90 | 2024 | Hyrimoz |
| Phathom Pharmaceuticals, INC. | $19.44 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $17.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2024 | Simlandi |
| Lilly USA, LLC | $15.35 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Picano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.